BLOCKsynop is a company focused on commercializing the Neural Blockade Monitor (NBM) for clinical pain management. The company's core activities involve developing and implementing the NBM technology, which enables objective and quantitative measurement of neural blocks. Wayne Sternberger, the CTO, leads the design and development efforts, while Robert S. Greenberg, MD, the CMO, guides the clinical perspective and interface requirements. Shari Sternberger, the President/CEO, oversees team support, organization growth, and product line development. Ellyn Murphy, as the Senior VP of Marketing, leads research, analysis, and implementation of clinician needs and solution marketing for BLOCKsynop.